https://www.prnewswire.com/news-releases/aridis-pharmaceuticals-receives-orphan-drug-designation-for-ar-501-300875809.html
AR-501
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
https://clinicaltrials.gov/ct2/show/NCT03669614?recrs=abdf&type=Intr&cond=Cystic+Fibrosis&lupd_s=02%2F12%2F2019&lupd_d=14
Condition : Cystic Fibrosis
Interventions : Drug: inhaled AR-501; Drug: inhaled AR-501 placebo
Sponsor : Aridis Pharmaceuticals, Inc.
Recruiting
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Thu, 13 Sep 2018 12:00:00 EDT
Last Update Posted: 02/26/19 10:27AM
